Here you can browse presentations from our inaugural Global Summit on Intellectual Property and Access to Medicines (GSIPA2M), which took place 15-17 January 2018, Marrakech, Morocco.
Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical companies to drive medicines where there is the greatest profit rather than the greatest need. 23 years later, our summit gathered people with the knowledge and skills to redress the balance.
View the speakers’ presentations by day and session below.
To view full-screen, click the arrows which can be found at the bottom right of each PowerPoint presentation.
Day 1: Opening session
Our opening session speakers were: Alia Amimi and Khadija El Gabsi, ITPC MENA, Morocco; Veriano Terto, ABIA, Brazil; Jorge Mermudez, UN High Level Panel on Access to Medicines; Solange Baptiste, ITPC Global, and representatives from the Government of Morocco.
Day 1: Plenary 1 – Two decades of TRIPS
Our first plenary session: Return to Marrakech: Two decades of TRIPS and access to medicines. The focus of the presentations included looking at the difference between the cost and prices of medicines; the use TRIPS flexibilities, asking whether they are enough; describing examples where they have been used; and looking at patent law reform as an option.
Day 1: Plenary 2 – The role of civil society
This session looked at the role of civil society in the implementation of TRIPS flexibilities . This included examples of challenging the tactics of ‘Big Pharma’, such as patent oppositions, compulsory licenses, patent law reform, and monitoring the effect of intellectual property on public health.
Day 1: Parallel session 1 – Preventing bad patents
This session looked at the role of patent examination in preventing unmerited patents. Views and experiences were shared by civil society organizations, lawyers, and others, including perspectives from the patent offices themselves.
Day 1: Parallel session 2 – Making CLs routine
Countries have a right under the TRIPS Agreement to issue compulsory licenses (CLs) in the interest of public health. However, pharmaceutical companies hit back hard because it reduces their exorbitant profits, even in cases when a patent is unmerited to begin with. Brook Baker (pictured) from Health GAP, moderated the session.
Day 2: Plenary 3 – Leaving TRIPS behind
Day 2 started by looking at Leaving TRIPS behind: Understanding and resisting TRIPS-plus measures. This included examining the impact of some trade agreement deals on access to medicines.
Day 2: Roundtable 1 – TRIPS-minus
This first roundtable discussed how ‘least developed countries’ (LDCs) can make effective use of the transition periods, including what civil society groups need to do to support their governments in maintaining their rights during this period.
Day 2: Roundtable 2 – Local production and technology transfer
The second roundtable of day 2 looked at local production and technology transfer, including why local production is so important, and government policies that can be employed to support this.
Day 2: Roundtable 3 – Pro-health patent law reform
Speakers addressed the possibilities and challenges in achieving law reform, which is essential to focus on as the continued over-protection of pharmaceutical companies is killing people.
Day 2: Roundtable 4 – Challenging unmerited patents
Looking at the successes and challenges in preventing or appealing unmerited patents – both from civil society and patent offices’ persepctives.
Day 2: Plenary panel – sustaining civil society work on IP
The final session of day 2 looked at how to sustain and support civil society work on intellectual property (IP) and access to medicines, which included hearing from two of the key donors of the Make Medicines Affordable campaign – UNITAID and aidsfonds.
Day 3: Closing plenary – A radical agenda?
We asked if what’s been described over the Summit with regards to patents and access to medicines is a radical agenda. We believe the agenda needs to be radical – and that these changes are also achievable.
Day 3: Rapporteur notes
Our closing session included some passionate speeches, referring back on what’s been said as well looking forward. During the session, the 2018 Leadership Award on Intellectual Property and Access to Medicines was granted to Malaysia’s Ministry of Health.